TrialClinical trialPHN-02642026-09-16 19:00 CT

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Source · ClinicalTrials.gov: elamipretide

TLDR

The ClinicalTrials.gov listing describes ReNEW as an active Phase 3 trial of elamipretide for dry age-related macular degeneration that is no longer recruiting. The study compares elamipretide with placebo to evaluate efficacy, safety and pharmacokinetics.

01—Key points

01The main efficacy question concerns the rate of change in the macular area of photoreceptor loss.
02The trial also evaluates elamipretide’s safety and tolerability.
03The provided excerpt describes the study design but reports no results.

Why it matters Editorial

The trial is evaluating whether elamipretide affects photoreceptor loss in dry AMD compared with placebo.

Read the original at ClinicalTrials.gov: elamipretide↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.